Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will be hosting a conference call at 5:00 PM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.ultragenyx.com
Earnings Expectation
Ultragenyx Pharmaceutical Inc. is reporting third quarter financial results on Tuesday 27th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, RARE is expected to report 3Q20 loss of $ 1.27 per share from revenue of $ 53.89 million.
For the full year, analysts anticipate top line of $ 209.26 million, while looking forward to loss of $ 4.39 per share bottom line.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia.
